Clinically recognizable error rate after the transfer of comprehensive chromosomal screened euploid embryos is low  by Werner, Marie D. et al.
Clinically recognizable error rate
after the transfer of comprehensive
chromosomal screened euploid
embryos is low
Marie D. Werner, M.D.,a Mark P. Leondires, M.D.,b William B. Schoolcraft, M.D., H.C.L.D.,c
Brad T. Miller, M.D.,d Alan B. Copperman, M.D.,e Edwin D. Robins, M.D.,f Francisco Arredondo, M.D., M.P.H.,g
Timothy N. Hickman, M.D.,h Jacqueline Gutmann, M.D.,i Wendy J. Schillings, M.D.,j Brynn Levy, Ph.D.,k
Deanne Taylor, Ph.D.,a,k Nathan R. Treff, Ph.D.,a,k and Richard T. Scott Jr., M.D., H.C.L.D.a,k
a Robert Wood Johnson Medical School of Rutgers University, New Brunswick, New Jersey; b Reproductive Medicine
Associates of Connecticut, Norwalk, Connecticut; c Colorado Center for Reproductive Medicine, Lone Tree, Colorado;
d Reproductive Medicine Associates of Michigan, Troy, Michigan; e Reproductive Medicine Associates of New York, New
York, New York; f Center for Reproductive Health, Spokane, Washington; g Reproductive Medicine Associates of Texas,
San Antonio, Texas; h Houston IVF, Houston, Texas; i Reproductive Medicine Associates of Philadelphia, Philadelphia,
Pennsylvania; j Reproductive Medicine Associates of Pennsylvania, Allentown, Pennsylvania; and k Reproductive
Medicine Associates of New Jersey, Basking Ridge, New JerseyObjective: To determine the clinically recognizable error rate with the use of quantitative polymerase chain reaction (qPCR)–based
comprehensive chromosomal screening (CCS).
Design: Retrospective study.
Setting: Multiple fertility centers.
Patient(s): All patients receiving euploid designated embryos.
Intervention(s): Trophectoderm biopsy for CCS.
Main Outcome Measure(s): Evaluation of the pregnancy outcomes following the transfer of qPCR-designated euploid embryos.
Calculation of the clinically recognizable error rate.
Result(s): A total of 3,168 transfers led to 2,354 pregnancies (74.3%). Of 4,794 CCS euploid embryos transferred, 2,976 gestational sacs
developed, reﬂecting a clinical implantation rate of 62.1%. In the cases where a miscarriage occurred and products of conception were
available for analysis, ten were ultimately found to be aneuploid. Seven were identiﬁed in the products of conception following clinical
losses and three in ongoing pregnancies. The clinically recognizable error rate per embryo designated as euploid was 0.21% (95%
conﬁdence interval [CI] 0.10–0.37). The clinically recognizable error rate per transfer was 0.32% (95% CI 0.16–0.56). The clinically
recognizable error rate per ongoing pregnancy was 0.13% (95% CI 0.03–0.37). Three products of conception from aneuploid losses
were available to the molecular laboratory for detailed examination, and all of them demonstrated fetal mosaicism.
Conclusion(s): The clinically recognizable error rate with qPCR-based CCS is real but quite low. Although evaluated in only a limited
number of specimens, mosaicism appears to play a prominent role in misdiagnoses. Mosaic errors present a genuine limit to theUse your smartphoneeffectiveness of aneuploidy screening, because they are not attributable to technical issues in
the embryology or analytic laboratories. (Fertil Steril 2014;102:1613–8. 2014 by
American Society for Reproductive Medicine.)
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VOL. 102 NO. 6 / DECEMBER 2014mbryonic aneuploidy screeningE has been used with success inassisted reproduction to improve
overall pregnancy outcomes. The
magnitude of improvement has been
demonstrated by class I data that have
shown the transfer of chromosomally
normal embryos screened by compre-
hensive chromosomal screening (CCS)
to signiﬁcantly increase implantation1613
ORIGINAL ARTICLE: ASSISTED REPRODUCTIONand delivery rates compared with unscreened embryos (1–3).
By selecting only euploid embryos for transfer, investigators
have also reported a reduced risk of clinical pregnancy loss
(4). Perhapsmost importantly, elective single-embryo transfer
with CCS-screened embryos provides delivery rates per trans-
fer equivalent to multiembryo transfer (5). The dramatic
reduction in polyzygotic multiple gestation meaningfully
enhances obstetrical and neonatal outcomes for patients
who conceive with the use of these technologies (6).
Although clinical results have been excellent, the reality
is that no screening paradigm is perfect. Embryonic aneu-
ploidy screening with CCS is subject to both biologic and
technical errors (7). Inevitably, that means that some patients
will develop aneuploid gestations even after undergoing CCS
during their IVF treatment cycle. A biologic error is any
misdiagnosis that results from a complexity within the
embryo rather than an error of test function. As such, biologic
errors are limitations of the test rather than errors of test func-
tion. For example, these tests require normalization of each
chromosome within a specimen against the other chromo-
somes within that same specimen (8, 9). This corrects for
variation in the number of the cells in the biopsy, the
loading volume when the biopsy is placed in the reaction
tube, and the variability in the ﬁdelity of the ampliﬁcation
itself. Therefore, haploidy, triploidy, and tetraploidy are not
currently predictable.
Perhaps most important is the broader impact of embry-
onic mosaicism (10, 11). There are two clinically relevant
types of mosaicism, that within the embryo and that within
the biopsy sample. When mosaicism exists elsewhere
within the embryo, an accurately processed and evaluated
biopsy may correctly be designated as euploid while some
portion of the embryo is aneuploid and may result in an
abnormal clinical gestation. However, when mosaicism
exists within the biopsy sample it can be detected with the
use of single-nucleotide polymorphism (SNP) microarray
whenR40% of the cells are mosaic and with the use of array
comparative genome hybridization (aCGH) when R50% are
aneuploid (12, 13).
Technical errors might be attributed to specimen process-
ing and handling, ampliﬁcation ﬁdelity, and a variety of fac-
tors affecting the informatics used to calculate the ﬁnal result.
Any one or more of these factors, alone or in combination
with the biologic factors, may compromise the predictive
value of the test and lead to the transfer of an embryo that
results in an aneuploid gestation.
Data evaluating the predictive value of a normal result
from quantitative polymerase chain reaction (qPCR) and
SNP microarray are available, and within those studies no
embryo that screened as euploid implanted and progressed
into a clinical aneuploid pregnancy (1, 2, 4). Similarly, data
are available evaluating the predictive value of a normal
result from 204 day-3 aCGH cycles; 13 miscarriages were
observed, three with evaluable products of conception, and
no misdiagnoses were identiﬁed although maternal contami-
nation was not excluded (14). The published misdiagnosis rate
with aCGH is 1.9%when comparing outcomes to ﬂuorescence
in situ hybridization (FISH) results, which is problematic
given the substantial error rate associated with FISH (15). In1614a comparative study, SNP microarray reanalysis indicated a
signiﬁcantly higher error rate with aCGH (7%) compared
with qPCR (0%) (16). Although this is reassuring that the clin-
ically recognizable error rate is low with all techniques, the
reality is that these studies were not powered to provide a
comprehensive evaluation of the false-normal rate of embry-
onic aneuploidy screening.
Unfortunately, clinical experience has shown that clinical
misdiagnoses do occur and that aneuploid gestations have
rarely developed after transferring embryos that were
screened as euploid (7). These pregnancies represent adverse
outcomes for patients. In those cases where the pregnancies
arrest in early development and miscarry, the patients suffer
the physical and emotional consequences of pregnancy loss
and lose valuable time from their efforts to conceive and
deliver a healthy gestation. Development into an ongoing
aneuploid gestation has even more complex and potentially
longstanding consequences for these patients.
Only very large clinical experiences would be sufﬁciently
powered to estimate how often these potentially serious
adverse outcomes result. The present study sought to review
a large multicentered clinical experience to determine how
often clinically detectable aneuploid gestations develop after
transferring embryos designated as euploid with the use
of CCS.MATERIALS AND METHODS
Experimental Design
All centers using CCS in conjunction with Reproductive
Medicine Associates Genetics were queried regarding the
outcomes of the cycles in which screened embryos were trans-
ferred. All transfer cycles from the participating centers were
reviewed to determine the following: 1) the total number of
transfers; 2) the total number of embryos transferred; 3) the
number of transfers where a clinical pregnancy was estab-
lished; 4) the number of transfers where no pregnancies
occurred; and 5) the number of transfers where evidence of
aneuploid gestation was found. In the event where an aneu-
ploid gestation was identiﬁed, the pregnancy was further
categorized as having resulted in either a clinical loss or an
ongoing/delivered gestation.
Owing to the multicenter and retrospective nature of the
study design, not all pregnancies that resulted in a loss had
fetal cellular material obtained for examination: 50% of
patients with a clinically recognized loss had an evaluation
with tissue for diagnosis, and 90% of those underwent
cytogenetic analysis; therefore, no conclusion can be drawn
from cases that did not undergo this procedure. In the case
of a misdiagnosis, the study center was alerted and all other
tested specimens were assumed to be of normal karyotype.
Clearly, this methodology is not comprehensive, because
some clinical pregnancies were lost but did not undergo
dilation and curettage and thus had no tissue available for
cytogenetic analysis. It is unknown if these losses were
euploid or aneuploid. Regarding pregnancies that delivered,
it seems very unlikely that an aneuploid gestation would
remain unrecognized by the couple or the clinicians caring
for the baby.VOL. 102 NO. 6 / DECEMBER 2014
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cellular material was available, a sample was obtained to
allow investigation of possible mosaicism. Individual cells
were isolated from each product of conception sample,
and several of these cells were tested. Microarray copy
number analysis and genotyping were performed on each
cell tested so that ploidy status could be determined in
addition to allowing DNA ﬁngerprinting and deﬁnitive
designation of the cells as being of maternal or fetal origin.
Once these criteria were satisﬁed, the chromosomal analysis
of fetal cells was compared with the original biopsy results.
If mosaicism was identiﬁed, then the error was considered
to be biologic in origin. If no mosaicism was identiﬁed,
then it was not possible to designate the error as being
either biologic or technical because it remained possible
that mosaicism existed in some part of the developing
conceptus which was not sampled and tested during the
analysis.
Participating Centers
The ten Reproductive Medicine Associates (RMA) centers that
participated included RMA of New Jersey, RMA of Connect-
icut, Colorado Center for Reproductive Medicine (CCRM),
RMA Michigan, RMA of New York, Spokane Center for
Reproductive Health, RMA of Texas, Houston IVF, RMA of
Philadelphia, and RMA of Pennsylvania–Allentown.
Every center was responsible for clinical care of their
patients and all related embryologic procedures. Each center
cultured embryos to the blastocyst stage and performed
trophectoderm biopsies that were subsequently loaded into
PCR tubes containing lysis buffer for analysis. The molecu-
lar genetics department at RMA Genetics in Basking Ridge,
New Jersey, performed qPCR ampliﬁcation steps which
included multiplex preampliﬁcation, qPCR, and bioinfor-
matics analysis for copy number determination. The
one exception was CCRM, which performed the preampliﬁ-
cation and qPCR internally before bioinformatics analysis
at RMA Genetics. The reagents and test plates for the ana-
lyses at CCRM were provided by RMA Genetics and were
identical to those used for the other assays. Final reports
were generated and forwarded to the program caring for
each patient.Outcomes and Data Analysis
The purpose of this retrospective observational study was to
determine the clinically recognizable error rate after the
transfer of embryos whose screening had indicated that
they were euploid. In this study, embryos with normal
screening results (either 46,XX or 46,XY) are described as
being ‘‘designated euploid.’’ All references to the ploidy status
of embryos before transfer refer to their screening result and
thus their designated status. Although this is not a routinely
used term, it seeks to emphasize that the true status of the
embryo is unknown. The present study speciﬁcally sought
to determine how often that designation is incorrect and leads
to a clinically recognizable error due to the establishment of
an aneuploid implantation.VOL. 102 NO. 6 / DECEMBER 2014The ﬁrst step in the analysis is to determine the number of
aneuploid implantations that occurred after transfer of
embryos that had been screened and designated as euploid.
Where products of conception are available, this is deter-
mined by analysis of products of conception after a clinical
loss, amniocentesis, or chorionic villi sampling of ongoing
implantations or cytogenetic analysis of a newborn suspected
to have an abnormality.
Given those data, the clinically recognizable error rate
per euploid embryo transferred can be calculated. The total
number of implantations found to be aneuploid is divided
by the total number of embryos transferred and expressed
as a percentage. It is also possible to calculate the proportion
of clinically evident implantations that were aneuploid.
That rate is determined by dividing the number of aneuploid
implantations by the total number of gestational sacs
identiﬁed. Finally, the subset of aneuploid implantations
which were ongoing (i.e., did not miscarry) may be used to
calculate the risk for an ongoing aneuploid implantation
per CCS-screened embryo transferred.
Clearly, these types of data cannot provide a comprehen-
sive evaluation of the overall misdiagnosis rate among
embryos designated as euploid. If the embryo either failed
to implant or arrested before developing a clinically evident
gestational sac, then there are no products of conception to
evaluate. Similarly, if the embryo implanted and a miscar-
riage occurred, only cases in which tissue was collected could
be evaluated. It is not possible to determine if the designation
of euploid for such embryos was correct or incorrect. It does
not mean that the screening results for those embryos were
incorrect, it only means that any misdiagnoses would be
undetectable. The only analyses possible with clinical data
are of the clinically recognizable error rate.
Evaluating the outcomes per transfer follows similar
logic. First, the overall clinically recognizable error rate per
transfer is calculated by dividing the number of pregnancies
that had an aneuploid implantation by the total number of
transfers. The risk of an ongoing aneuploid gestation is deter-
mined by dividing the number of pregnancies with an
ongoing aneuploid implantation by the number of transfers.
The ﬁnal analysis was based on the evaluation of the
products of conception from those aneuploid implantations
where cellular material was made available to the analytic
laboratory doing the CCS testing. Comparison of SNP micro-
array analysis proﬁles were compared to determine the pres-
ence or absence of embryonic mosaicism. The mosaicism rate
among the aneuploid embryos was reported as a percentage of
the samples that were available for analyses. This analysis
was approved by the Western Institutional Review Board,
protocol no. 20021333.RESULTS
The outcomes of cycles using qPCR-based aneuploidy
screening from January 2010 to June 2013 were available for
analysis. A total of 3,168 transfers involving 4,974 blastocysts
that had been designated as being euploid by CCS were
completed.1615
TABLE 1
Clinically recognizable error rate per designated euploid embryo
(N = 4,794).
Parameter Evaluated N (% of total)
Embryos developed into clinically
evident gestational sacs, n (%)
2,976 (62.1)
Embryos progressed to delivery, n (%) 2,738 (57.1)
Clinically evident
gestational sacs that
arrested in
development and
did not deliver, n (%)
238 (8.0)a
Clinically recognizable
errors per embryo
Clinically
recognizable error
rate per embryo (%) 95% CI
Total (n ¼ 10) 0.21 0.10–0.37
Ongoing (n ¼ 3) 0.10 0.03–0.27
Note: CI ¼ conﬁdence interval.
a Percent of clinically evident gestational sacs.
Werner. Error rate with comprehensive chromosomal screening. Fertil Steril 2014.
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Of the 4,974 blastocysts transferred, 2,976 gestational sacs
developed, providing a clinical implantation rate of 62.1%.
Of those, 2,738 (92%) progressed to delivery and 238 (8%)
either miscarried or underwent spontaneous reduction. Ulti-
mately, 57.1% of transferred embryos implanted and
progressed to delivery.
Ten of the implantations where products of conception
were available for analysis were found to be aneuploid. These
included one tetraploid, two monosomic, and seven trisomic
gestations. Seven of these aneuploid gestations were identi-
ﬁed in ﬁrst-trimester clinical pregnancy losses, and the
remaining three were identiﬁed in the early second trimester
of ongoing gestations.
The clinically recognizable error rate per embryo desig-
nated as euploid was 10 out of 4,974, or 0.21% (95% conﬁ-
dence interval [CI] 0.10%–0.37%). Three of these aneuploid
gestations were found in ongoing gestations, so the propor-
tion of screened embryos that ultimately resulted in an
ongoing aneuploid gestation was 3 out of 4,974, or 0.06%.
The clinically recognizable error rate may also be
expressed as a proportion of total gestational sacs. A total
of 10 out of 2,976 (0.3%) gestational sacs were discovered
to be aneuploid. The clinically recognizable error rate among
the ongoing gestational sacs was 3 out of 2,976, or 0.1%.TABLE 2Analyses per Transfer
There were a total of 3,168 transfers using embryos that had
been designated as euploid with the use of CCS. A mean of
1.5 embryos were included per transfer. A total of 2,354
(74.3%) of the transfers progressed to the point of having
one or more gestational sacs. Of these, 2,189 developed into
ongoing pregnancies, providing a delivery rate per transfer
of 69.1%.
The 10 errors occurred in 10 separate pregnancies. The
clinically recognizable error rate per transfer was 10 out of
3,168, or 0.32% (95% CI 0.16%–0.56%). The clinically recog-
nizable error rate per clinical pregnancy was 10 out of 2,354,
or 0.4%. Finally, ongoing aneuploid gestations occurred in 3
out of 2,184 ongoing pregnancies, or 0.13%. Speciﬁc numbers
for each are presented in Tables 1 and 2.Clinically recognizable error rate per transfer (N = 3,168).
Parameter Evaluated N (% of total)
Clinical pregnancies (R1 gestational
sacs), n (%)
2,354 (74.3)
Pregnancies progressed
to delivery, n (%)
2,189 (69.1)
Clinically evident
gestational sacs that arrested in
development and did
not deliver, n (%)
170 (7.2)a
Clinically recognizable
errors per transfer
Clinically
recognizable error
rate per transfer (%) 95% CI
Total (n ¼ 10) 0.32 0.16–0.56
Ongoing (n ¼ 3) 0.13 0.03–0.37
Note: CI ¼ conﬁdence interval.
a Percent of pregnancies.
Werner. Error rate with comprehensive chromosomal screening. Fertil Steril 2014.Evaluation for Possible Mosaicism
There were four cases in which products of conception were
available for comparison and all underwent detailed analysis
to conﬁrm the origin of misdiagnosis. In all four cases the
products of conception showed evidence of mosaicism. For
example, one case followed the transfer of an embryo with
a predicted karyotype of 46,XY. The products of conception
were analyzed with the use of routine g-banded karyotype
analysis and determined to be 47,XYþ15, yielding an
abnormal male karyotype that contradicted the predicted
result. SNP microarray analysis with copy number analysis
and genotyping demonstrated clear evidence of mosaicism
with some fetal cells exhibiting the predicted euploid karyo-
type (46,XY) and the remainder of the cells exhibiting the
aneuploid karyotype (47,XYþ15).1616DISCUSSION
This study details a large multicenter experience with qPCR-
based aneuploidy screening which allowed characterization
of the clinically recognizable error rate. This information
should be helpful when counseling patients about the clinical
results that may be anticipated following the transfer of em-
bryos that have undergone CCS-based aneuploidy screening.
It also provides some insights into the mechanisms that lead
to these clinical failures.
The clinical utility of 24-chromosome aneuploidy
screening has been validated in several studies providing class
I data (1, 2, 4, 9, 17). Increased implantation rates, lower loss
rates, and higher delivery rates have all been demonstrated (2,
5, 6). Although enthusiasm for these enhanced outcomes is
reasonable, it should be tempered by acknowledgement of
the inevitable misdiagnoses that accompany the use of any
laboratory diagnostic test.VOL. 102 NO. 6 / DECEMBER 2014
Fertility and Sterility®Misdiagnoses are known to occur with all forms of preim-
plantation genetic diagnosis. The European Society for
Human Reproduction and Embryology Preimplantation
Genetic Diagnosis (PGD) Consortium reported a 0.27% rate
per transfer of misdiagnoses for qPCR-based PGD for single
gene disorders. There was also a relatively high error rate of
3.6% when performing sex determination for X-linked
diseases (18). Preimplantation genetic screening has evolved
with introduction of routine trophectoderm biopsy and
different analytic testing platforms. The new paradigms
may provide greater speed and accuracy as well as potentially
reduced costs. However, no technique is perfect and it is
important to measure both the actual and the clinically recog-
nizable error rates.
The initial study deﬁning the limits to the predictive value
of 24-chromosome aneuploidy screening was a prospective
blinded nonselection study (1). That study sought to deter-
mine the false-positive (embryo predicted to be abnormal
but a healthy child resulted) and the false-negative rate
(embryo predicted to be euploid but an aneuploid gestation
developed after transfer) by biopsying embryos and then
transferring them to the patients without waiting for any
analysis of that biopsy. The results of the analysis were even-
tually correlated with the ultimate outcomes for those
embryos. That nonselection study calculated the clinically
recognizable error rate of a euploid screening result. Specif-
ically, it found that the clinically recognizable error rate
was zero because there were no misdiagnoses following the
transfer of embryos that were designated as euploid after CCS.
Those data were certainly reassuring, but the small sam-
ple size signiﬁcantly limited their power. Implantation and
progression of an aneuploid embryo to a clinical stage of
development occurs relatively infrequently (1). That means
that the chance of an error being detected in a clinical implan-
tation is low even if the embryo is mislabeled as being euploid
when in fact it is aneuploid. Further complexity is added by
the fact that embryonic mosaicism may allow euploid cells
to be biopsied and correctly labeled as euploid when the em-
bryo contains a substantial amount of aneuploid cells and
may subsequently develop into an abnormal gestation. The
clinically recognizable error rate of a euploid CCS result is a
function of many factors. These include a combination of
the laboratory error rate, the prevalence of embryonic mosa-
icism, and the relatively low efﬁciency with which aneuploid
embryos implant and progress to clinically evaluable stages
of development.
The most challenging of the sources of clinically recog-
nizable errors may ultimately be mosaicism. Given the reality
of embryonic mosaicism, even at the blastocyst stage, it is
unlikely that any testing paradigm will ever attain perfect
precision. Interestingly, all four cases where a portion of the
products of conception were provided to the CCS laboratory
showed clear evidence of mosaicism. In these cases, the
biopsy may very well have been normal despite sufﬁcient
aneuploid cells being present in the embryo to create an
abnormal pregnancy. These errors may be the result of a
biologic error (mosaicism), an analytic error, or both in the
event that the biopsy itself was mosaic but went undetected
in the analysis.VOL. 102 NO. 6 / DECEMBER 2014Given the unavailability of cellular material, it is
unknown if any of the other aneuploid pregnancies were
mosaic or if they represented analytic errors. An analytic error
occurred in at least one case. The normalization and statistical
smoothing required for qPCR-based CCS means the technique
is currently incapable of detecting tetraploidy. In the end, it
seems likely that the errors reﬂected both biologic and
laboratory-related issues.
In the future, it may be possible to determine if mosaicism
is present in the biopsy. Next-generation sequencing (NGS)
has great potential to detect mosaicism in that setting. Still,
that would require that mosaicism exist in the small amount
of trophectoderm removed at the time of the biopsy, typically
3–5 cells. It is certainly possible that a great deal of mosai-
cism, although signiﬁcantly affecting the embryo, would
remain undetected because it may not be represented in the
biopsy itself. Some NGS protocols may also be able to identify
polyploid samples. Additionally, it may become possible to
integrate these data with those of other types of evaluations,
such as time-lapse imaging or assessment of the transcrip-
tome of the cumulus, to further enhance selection and
improve clinical outcomes. Studies evaluating all of these
approaches are underway.
In the end, the greatest value of the data from the present
study may be in empowering accurate patient counseling for
those couples considering embryonic aneuploidy screening.
Our group has elected to focus on three speciﬁc pieces of
information when using these data to counsel patients.
They are the clinically recognizable error rate per embryo
tested, which is 0.21%, the clinically recognizable error rate
per transfer, which is 0.32%, and the risk of an ongoing aneu-
ploid gestation per transfer, which is 0.13%. We also empha-
size that these are the clinically recognizable error rates found
only in evaluable pregnancies and does not account for the
error rate in embryos that do not implant or progress to the
clinical stage. It should be emphasized that not every miscar-
riage had products available for conception, and so the clin-
ically recognizable error rate can not account for those
pregnancies that miscarried and no subsequent analysis was
performed. Assuming 45% of all miscarriages underwent
cytogenetic analysis, in the worst case scenario this would
mean that 6.5% of all miscarriages were aneuploid, and a
hypothetic misdiagnosis would occur in 0.40% of embryos.
This would be an overestimate of the misdiagnosis rate, but
it is interesting to postulate a worst-case scenario given the
limitation of this study design.
It would be most helpful if it were possible to determine if
the misdiagnosis risk varied for different subpopulations of
patients. Clinicians and patients may choose CCS testing for
speciﬁc risk factors, such as increasing age, recurrent implan-
tation failure, diminished ovarian reserve, and other factors
traditionally associated with an increased risk of aneuploidy.
Differences in mosaicism and other unknown factors may
inﬂuence the validity of the diagnostic result. In this way,
the present analysis may not be directly applicable to all cases
and would require a large sample size, given the very low
prevalence of clinically recognizable errors.
These data may also be useful in discussions with obste-
tricians, perinatologists, and geneticists who counsel and care1617
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they and the patients need to remain vigilant to the fact that
aneuploid gestations may occur even after embryonic aneu-
ploidy screening. Indications for ﬁrst- and second-trimester
antenatal screening should remain unchanged. The chance
of ﬁnding an abnormality is reduced but clearly not elimi-
nated. At the present time, there is no validated way to adjust
the risk calculations used during antenatal screening. In the
future, as more data accrue, it may be possible to incorporate
the fact that CCS was done when considering calculation of
aneuploidy risk following serum or ultrasound screening
paradigms.
In conclusion, the use of qPCR-based CCS results in a very
low risk for a clinically recognizable aneuploid pregnancy.
New technologies, adjunctive screening of the embryo, and
enhanced clinical management strategies offer opportunities
for further improvements in the precision of the screening
result and possibly clinical outcomes. Studies validating the
use of more advanced technologies and screening paradigms
are already ongoing.
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